Home › Research › Down syndrome and Alzheimer's
Cytonectin expression in Alzheimer disease
Anderson SJ, Barker PE, Hadfield MG.. Journal of neuropathology and experimental neurology, 2002-03-01
Topic: Amyloid, tau and blood-test diagnosis
Cytonectin is a novel 35,000 molecular weight protein that displays remarkable ion-independent adherence properties. This consigns it to a family of well-known adherence molecules essential for cell communication and the development of 3-dimensional tissue structures. Cytonectin is expressed in a variety of organs and tissues, being evolutionarily conserved from human to avian species. It is hypothesized to serve as a key structural component of the body, and as a "do not attack" signal molecule that prevents tissue destruction by cells of monocyte lineage. This paper describes the properties of cytonectin and its proposed role in normal and disease states. The protein is overexpressed in Alzheimer disease entorhinal cortex as compared to normal age-matched controls. It is also detected in tissues from patients with Down syndrome and leukemia. Its presence in all 3 of these related conditions may prove important to their etiopathogenesis.
Key findings
- The protein is overexpressed in Alzheimer disease entorhinal cortex as compared to normal age-matched controls.
Why it matters
This paper describes the protein cytonectin and reports that it is overexpressed in the entorhinal cortex in Alzheimer disease. It is a descriptive report of a protein's presence and proposes a possible role, without testing any treatment, cure or prevention.
Study details
- Evidence strengthLow
How this study scored 27/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 26 of the 96 points we could judge it on, which is 27 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of neuropathology and experimental neurology) |
| Journal's citation record | 2 / 4 | Journal of Neuropathology & Experimental Neurology: journal h-index 239 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2002 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 26 year(s) since 2002 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 1 / 3 | National Institute of Standards and Technology: institution h-index 879 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 11895037) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 26 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 26 of the 96 points we could judge it on is 27 out of 100. |
| Total | 27 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Anderson, S. J., Barker, P. E., & Hadfield, M. G. (2002). Cytonectin expression in Alzheimer disease. Journal of neuropathology and experimental neurology. https://doi.org/10.1093/jnen/61.3.230
Vancouver
Anderson SJ, Barker PE, Hadfield MG. Cytonectin expression in Alzheimer disease. Journal of neuropathology and experimental neurology. 2002. doi:10.1093/jnen/61.3.230. PMID: 11895037.
BibTeX
@article{anderson2002-11895037,
author = {Anderson, S. J. and Barker, P. E. and Hadfield, M. G.},
title = {{Cytonectin expression in Alzheimer disease}},
journal = {Journal of neuropathology and experimental neurology},
year = {2002},
doi = {10.1093/jnen/61.3.230},
pmid = {11895037},
url = {https://doi.org/10.1093/jnen/61.3.230}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Down syndrome and Alzheimer's
Also tagged “down”
527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.